Coronavirus Update: Lilly To Seek EUA For Olumiant
Plus: Gilead Agrees European Procurement Deal On Veklury
Hot on the heels of positive news from its monoclonal antibody treatment, Lilly aims to seek emergency authorization for anti-inflammatory treatment Olumiant.
You may also be interested in...
Following last month’s data showing reduced hospitalization risk with single neutralizing antibody therapy, Lilly now has data showing a two-antibody combo reduces COVID-19 viral load significantly.
Meanwhile, seven former US FDA commissioners issue joint plea for trust in the scientific integrity of the agency.
Johnson & Johnson has released early data putting its COVID-19 vaccine broadly in line with frontrunners from Pfizer and Moderna, but with key advantage of requiring just one injection.